Gsk (GSK) Receivables (2016 - 2025)

Gsk (GSK) has 10 years of Receivables data on file, last reported at $11.5 billion in Q4 2025.

• In Q4 2025, Receivables rose 16.1% year-over-year to $11.5 billion; the TTM figure through Dec 2025 stood at $11.5 billion (up 16.1% YoY), while the FY2025 annual figure was $11.5 billion, up 16.1% from the prior year.
• Receivables climbed to $11.5 billion in Q4 2025, from $9.9 billion in the prior quarter.
• Across five years, Receivables topped out at $12.3 billion in Q4 2021 and bottomed at $9.7 billion in Q4 2022.
• A 5-year average of $10.8 billion and a median of $10.5 billion in 2023 frame the typical range for Receivables.
• Annual changes were most pronounced in 2021 — Receivables increased 16.91% — and 2022, when it retreated 21.06%.
• Year by year, Receivables stood at $12.3 billion in 2021, then decreased by 21.06% to $9.7 billion in 2022, then grew by 7.75% to $10.5 billion in 2023, then slipped by 5.63% to $9.9 billion in 2024, then rose by 16.1% to $11.5 billion in 2025.
• The last three Receivables figures came in at $11.5 billion (Q4 2025), $9.9 billion (Q4 2024), and $10.5 billion (Q4 2023), per Business Quant data.

Peer Comparison